All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What factors influence the adoption rates of novel MM therapies in Latin America?
Featured
Bookmark this article
The Multiple Myeloma Hub was pleased to speak to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked: What factors influence the adoption rates of novel multiple myeloma (MM) therapies in Latin America?
What factors influence the adoption rates of novel MM therapies in Latin America?
In this video interview, Vania Hungria provides an overview of the MM landscape in Latin America, focusing on the differences in access and adoption of novel therapies in public and private health care facilities. Hungria discusses the distribution of treatment between public and private institutions and the outcomes associated with treatment in each type of center.
More about...
Your opinion matters
28 votes - 3 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox